Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04130061 · ClinicalTrials.gov registry record · Early Phase 1
Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation
A Early Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 27
- Enrollment target
NCT04130061 is a Early Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 27 participants.
The verdict
NCT04130061, a Early Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study will evaluate the application of hAM at the time of cardiac surgery to decrease inflammation and the subsequent substrate to reduce incidence of post-operative atrial fibrillation. Patients will randomized 1:1 to receive either hAM application or standard of care.
Interventions
- BIOLOGICAL Human Amniotic Membrane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-10-11 |
| Est. Completion | 2021-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04130061
The ClinicalTrials.gov registry entry for NCT04130061 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Human Amniotic Membrane is the first listed.
NCT04130061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04130061 about?
NCT04130061 is a clinical study titled "Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation". This study will evaluate the application of hAM at the time of cardiac surgery to decrease inflammation and the subsequent substrate to reduce incidence of post-operative atrial fibrillation. Patients will randomized 1:1 to receive either hAM application or standard of care.
What is the current status of trial NCT04130061?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 27 participants. The study started on 2019-10-11. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT04130061?
The interventions under investigation include: Human Amniotic Membrane (BIOLOGICAL).
Who is sponsoring clinical trial NCT04130061?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.